Matthew J A Wood

List of Publications by Year in Descending Order

226 papers	26,372 citations	73 h-index	161 g-index
246 ext. papers	31,762 ext. citations	10.6 avg, IF	7.34 L-index

#	Paper	IF	Citations
226	Control of backbone chemistry and chirality boost oligonucleotide splice switching activity.. *Nucleic Acids Research*, **2022**,	20.1	6
225	Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model.. *Molecular Therapy - Nucleic Acids*, **2022**, 27, 1146-1155	10.7	2
224	Enhancing the Therapeutic Potential of Extracellular Vesicles Using Peptide Technology. *Methods in Molecular Biology*, **2022**, 2383, 119-141	1.4	1
223	AR cooperates with SMAD4 to maintain skeletal muscle homeostasis.. *Acta Neuropathologica*, **2022**, 143, 713-731	14.3	1
222	Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles. *Nature Biomedical Engineering*, **2021**, 5, 1084-1098	19	2
221	Fine Tuning of Phosphorothioate Inclusion in 2SO-Methyl Oligonucleotides Contributes to Specific Cell Targeting for Splice-Switching Modulation. *Frontiers in Physiology*, **2021**, 12, 689179	4.6	
220	Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides. *Nucleic Acid Therapeutics*, **2021**, 31, 172-181	4.8	4
219	Improving assessments of data-limited populations using life-history theory. *Journal of Applied Ecology*, **2021**, 58, 1225-1236	5.8	0
218	Profiling of Extracellular Small RNAs Highlights a Strong Bias towards Non-Vesicular Secretion. *Cells*, **2021**, 10,	7.9	3
217	Mesyl Phosphoramidate Oligonucleotides as Potential Splice-Switching Agents: Impact of Backbone Structure on Activity and Intracellular Localization. *Nucleic Acid Therapeutics*, **2021**, 31, 190-200	4.8	5
216	Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases. *Journal of Neuromuscular Diseases*, **2021**, 8, 869-884	5	4
215	Engineered extracellular vesicle decoy receptor-mediated modulation of the IL6 trans-signalling pathway in muscle. *Biomaterials*, **2021**, 266, 120435	15.6	8
214	Molecular and electrophysiological features of spinocerebellar ataxia type seven in induced pluripotent stem cells. *PLoS ONE*, **2021**, 16, e0247434	3.7	0
213	Targeting the 5Suntranslated region of as a therapeutic strategy for spinal muscular atrophy. *Molecular Therapy - Nucleic Acids*, **2021**, 23, 731-742	10.7	0
212	Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. *JCI Insight*, **2021**, 6,	9.9	1
211	Extracellular vesicles as a next-generation drug delivery platform. *Nature Nanotechnology*, **2021**, 16, 748-759	28.7	138
210	Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity. *Science Advances*, **2021**, 7,	14.3	4

209	RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis. *EMBO Journal*, **2021**, 40, e107680	13	3
208	Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy. *Molecular Therapy - Nucleic Acids*, **2021**, 26, 174-191	10.7	2
207	Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. *RNA Biology*, **2021**, 18, 1048-1062	4.8	6
206	GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. *Nature Communications*, **2021**, 12, 6666	17.4	6
205	MiR-219a-5p Enriched Extracellular Vesicles Induce OPC Differentiation and EAE Improvement More Efficiently Than Liposomes and Polymeric Nanoparticles. *Pharmaceutics*, **2020**, 12,	6.4	26
204	A CRISPR-Cas9-based reporter system for single-cell detection of extracellular vesicle-mediated functional transfer of RNA. *Nature Communications*, **2020**, 11, 1113	17.4	56
203	Exosomes mediate sensory hair cell protection in the inner ear. *Journal of Clinical Investigation*, **2020**, 130, 2657-2672	15.9	32
202	Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion. *Methods in Molecular Biology*, **2020**, 2176, 185-208	1.4	0
201	Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology. *Journal of Cachexia, Sarcopenia and Muscle*, **2020**, 11, 578-593	10.3	13
200	Doublecortin-like Kinase 1 Regulates Synuclein Levels and Toxicity. *Journal of Neuroscience*, **2020**, 40, 459-477	6.6	7
199	An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress. *Neurobiology of Disease*, **2020**, 144, 105050	7.5	7
198	Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy. *Molecular and Cellular Proteomics*, **2020**, 19, 2047-2068	7.6	5
197	Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1. *Molecular Therapy*, **2020**, 28, 2527-2539	11.7	6
196	Efficient Doxorubicin Loading to Isolated Dexosomes of Immature JAWSII Cells: Formulated and Characterized as the Bionanomaterial. *Materials*, **2020**, 13,	3.5	1
195	Advances in oligonucleotide drug delivery. *Nature Reviews Drug Discovery*, **2020**, 19, 673-694	64.1	407
194	Extracellular vesicles in neurodegenerative disorders **2020**, 285-305		5
193	Wrangling RNA: Antisense oligonucleotides for neurological disorders. *Science Translational Medicine*, **2019**, 11,	17.5	7
192	The viral protein corona directs viral pathogenesis and amyloid aggregation. *Nature Communications*, **2019**, 10, 2331	17.4	103

191	The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. *Human Molecular Genetics*, **2019**, 28, 2189-2200	5.6	21
190	Extracellular microRNAs exhibit sequence-dependent stability and cellular release kinetics. *RNA Biology*, **2019**, 16, 696-706	4.8	18
189	Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. *Experimental and Molecular Medicine*, **2019**, 51, 1-12	12.8	224
188	Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy. *Methods in Molecular Biology*, **2019**, 2036, 221-236	1.4	5
187	Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. *EBioMedicine*, **2019**, 45, 630-645	8.8	34
186	Considerations and Implications in the Purification of Extracellular Vesicles - A Cautionary Tale. *Frontiers in Neuroscience*, **2019**, 13, 1067	5.1	21
185	Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice. *Journal of Clinical Investigation*, **2019**, 129, 4739-4744	15.9	38
184	Exosome-Mediated miR-29 Transfer Reduces Muscle Atrophy and Kidney Fibrosis in Mice. *Molecular Therapy*, **2019**, 27, 571-583	11.7	68
183	Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment. *Nucleic Acid Therapeutics*, **2019**, 29, 1-12	4.8	51
182	Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice. *Gene Therapy*, **2019**, 27, 505-515	4	4
181	Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment. *Human Molecular Genetics*, **2019**, 28, 396-406	5.6	8
180	Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD. *Human Molecular Genetics*, **2019**, 28, 307-319	5.6	18
179	Extracellular Vesicle Heterogeneity: Subpopulations, Isolation Techniques, and Diverse Functions in Cancer Progression. *Frontiers in Immunology*, **2018**, 9, 738	8.4	343
178	Heterogeneity and interplay of the extracellular vesicle small RNA transcriptome and proteome. *Scientific Reports*, **2018**, 8, 10813	4.9	63
177	Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. *EBioMedicine*, **2018**, 31, 226-242	8.8	24
176	Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy. *PLoS ONE*, **2018**, 13, e0198897	3.7	12
175	Antisense oligonucleotides: the next frontier for treatment of neurological disorders. *Nature Reviews Neurology*, **2018**, 14, 9-21	15	301
174	UFLC-Derived CSF Extracellular Vesicle Origin and Proteome. *Proteomics*, **2018**, 18, e1800257	4.8	18

173	Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice. *Human Molecular Genetics*, **2018**, 27, 3582-3597	5.6	5
172	Comprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals Novel Small RNA Signatures with Biomarker Potential for DMD. *Molecular Therapy - Nucleic Acids*, **2018**, 13, 1-15	10.7	24
171	Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy. *Nucleic Acid Therapeutics*, **2017**, 27, 130-143	4.8	35
170	Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles. *Molecular Therapy*, **2017**, 25, 1580-1587	11.7	99
169	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. *Brain*, **2017**, 140, 887-897	11.2	94
168	Preparation and Isolation of siRNA-Loaded Extracellular Vesicles. *Methods in Molecular Biology*, **2017**, 1545, 197-204	1.4	4
167	Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy. *Trends in Molecular Medicine*, **2017**, 23, 989-1001	11.5	30
166	Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons. *Human Molecular Genetics*, **2017**, 26, 4441-4450	5.6	78
165	Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography. *Scientific Reports*, **2017**, 7, 11561	4.9	111
164	BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis. *Scientific Reports*, **2017**, 7, 6153	4.9	26
163	Therapeutic strategies for spinal muscular atrophy: SMN and beyond. *DMM Disease Models and Mechanisms*, **2017**, 10, 943-954	4.1	49
162	Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. *Human Molecular Genetics*, **2017**, 26, R151-R159	5.6	41
161	Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7. *Nucleic Acids Research*, **2017**, 45, 7870-7885	20.1	10
160	Targeting blood-brain-barrier transcytosis - perspectives for drug delivery. *Neuropharmacology*, **2017**, 120, 4-7	5.5	59
159	Splice-Switching Therapy for Spinal Muscular Atrophy. *Genes*, **2017**, 8,	4.2	15
158	Cells release subpopulations of exosomes with distinct molecular and biological properties. *Scientific Reports*, **2016**, 6, 22519	4.9	523
157	Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice. *Nature Communications*, **2016**, 7, 10981	17.4	40
156	Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 10962-7	11.5	116

155	Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. *Lancet Neurology, The*, **2016**, 15, 882-890	24.1	58
154	Peptides for nucleic acid delivery. *Advanced Drug Delivery Reviews*, **2016**, 106, 172-182	18.5	136
153	Lipid-based Transfection Reagents Exhibit Cryo-induced Increase in Transfection Efficiency. *Molecular Therapy - Nucleic Acids*, **2016**, 5, e290	10.7	6
152	Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases. *European Journal of Human Genetics*, **2016**, 24, 271-6	5.3	1
151	Proteostasis and Diseases of the Motor Unit. *Frontiers in Molecular Neuroscience*, **2016**, 9, 164	6.1	4
150	Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. *Human Molecular Genetics*, **2016**, 25, 3555-3563	5.6	18
149	mRNA and microRNA transcriptomics analyses in a murine model of dystrophin loss and therapeutic restoration. *Genomics Data*, **2016**, 7, 88-9		2
148	Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER. *Journal of Cell Biology*, **2016**, 213, 173-84	7.3	244
147	Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. *Nature Reviews Neurology*, **2016**, 12, 346-57	15	190
146	Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation. *Human Molecular Genetics*, **2016**, 25, 3960-3974	5.6	29
145	Using siRNA to define functional interactions between melanopsin and multiple G Protein partners. *Cellular and Molecular Life Sciences*, **2015**, 72, 165-79	10.3	25
144	Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?. *Neurodegenerative Disease Management*, **2015**, 5, 93-5	2.8	2
143	Therapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles. *Human Gene Therapy*, **2015**, 26, 506-17	4.8	105
142	Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides. *Nano Letters*, **2015**, 15, 4364-73	11.5	68
141	Extracellular vesicle-mediated delivery of molecular compounds into gametes and embryos: learning from nature. *Human Reproduction Update*, **2015**, 21, 627-39	15.8	39
140	Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2015**, 11, 879-83	6	338
139	Delivery of therapeutic oligonucleotides with cell penetrating peptides. *Advanced Drug Delivery Reviews*, **2015**, 87, 52-67	18.5	182
138	Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy. *Nucleic Acids Research*, **2015**, 43, 29-39	20.1	25

137	Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies. *Human Molecular Genetics*, **2015**, 24, 4916-32	5.6	38
136	An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. *Current Opinion in Pharmacology*, **2015**, 24, 52-8	5.1	101
135	Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. *Human Molecular Genetics*, **2015**, 24, 6756-68	5.6	30
134	Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. *Journal of Extracellular Vesicles*, **2015**, 4, 26316	16.4	711
133	Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. *Scientific Reports*, **2015**, 5, 8986	4.9	31
132	Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy. *Scientific Reports*, **2015**, 5, 11632	4.9	10
131	Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. *Scientific Reports*, **2015**, 5, 17014	4.9	37
130	Autologous Peripheral Blood Mononuclear Cells as Treatment in Refractory Acute Respiratory Distress Syndrome. *Respiration*, **2015**, 90, 481-92	3.7	9
129	Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. *Molecules*, **2015**, 20, 8823-55	4.8	53
128	Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods. *PLoS ONE*, **2015**, 10, e0145686	3.7	359
127	How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. *Human Molecular Genetics*, **2015**, 24, 4225-37	5.6	82
126	Isoforms of Melanopsin Mediate Different Behavioral Responses to Light. *Current Biology*, **2015**, 25, 2430-4	9.5	24
125	Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides. *Nucleic Acid Therapeutics*, **2015**, 25, 65-77	4.8	12
124	Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. *Nature Medicine*, **2015**, 21, 270-5	50.5	205
123	Serum-free culture alters the quantity and protein composition of neuroblastoma-derived extracellular vesicles. *Journal of Extracellular Vesicles*, **2015**, 4, 26883	16.4	85
122	Extracellular vesicles: emerging targets for cancer therapy. *Trends in Molecular Medicine*, **2014**, 20, 385-93	11.5	277
121	From gut to brain: bioencapsulated therapeutic protein reduces amyloid load upon oral delivery. *Molecular Therapy*, **2014**, 22, 485-486	11.7	10
120	Dispersal in a patchy landscape reveals contrasting determinants of infection in a wild avian malaria system. *Journal of Animal Ecology*, **2014**, 83, 429-39	4.7	15

119	Cross-talking noncoding RNAs contribute to cell-specific neurodegeneration in SCA7. *Nature Structural and Molecular Biology*, **2014**, 21, 955-961	17.6	64
118	The role of long non-coding RNAs in neurodevelopment, brain function and neurological disease. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2014**, 369,	5.8	133
117	Design and application of bispecific splice-switching oligonucleotides. *Nucleic Acid Therapeutics*, **2014**, 24, 13-24	4.8	4
116	Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides. *Molecular Therapy - Nucleic Acids*, **2014**, 3, e212	10.7	7
115	Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts. *European Journal of Human Genetics*, **2014**, 22, 1369-75	5.3	23
114	Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. *Nucleic Acids Research*, **2014**, 42, 3207-17	20.1	60
113	Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. *Movement Disorders*, **2014**, 29, 1476-85	7	286
112	Detection and quantification of extracellular microRNAs in murine biofluids. *Biological Procedures Online*, **2014**, 16, 5	8.3	29
111	Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. *Journal of Clinical Investigation*, **2014**, 124, 4067-81	15.9	29
110	Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine serum. *PLoS ONE*, **2014**, 9, e89237	3.7	82
109	The CRTC1-SIK1 pathway regulates entrainment of the circadian clock. *Cell*, **2013**, 154, 1100-1111	56.2	125
108	Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. *Human Gene Therapy*, **2013**, 24, 479-88	4.8	103
107	Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy. *Neurotherapeutics*, **2013**, 10, 621-31	6.4	39
106	Exosomes for targeted siRNA delivery across biological barriers. *Advanced Drug Delivery Reviews*, **2013**, 65, 391-7	18.5	338
105	Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. *Journal of Controlled Release*, **2013**, 172, 229-238	11.7	333
104	Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy. *Nature Medicine*, **2013**, 19, 351-7	50.5	169
103	Spatial determinants of infection risk in a multi-species avian malaria system. *Ecography*, **2013**, 36, 587-598	6.5	27
102	Extracellular vesicles: biology and emerging therapeutic opportunities. *Nature Reviews Drug Discovery*, **2013**, 12, 347-57	64.1	1894

101	Splicing therapy for neuromuscular disease. *Molecular and Cellular Neurosciences*, **2013**, 56, 169-85	4.8	64
100	Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. *Nature Reviews Genetics*, **2013**, 14, 373-8	30.1	176
99	Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. *Nucleic Acids Research*, **2013**, 41, 9500-13	20.1	68
98	Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. *BioMed Research International*, **2013**, 2013, 402369	3	38
97	Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-2 chain-null congenital muscular dystrophy mice. *Human Molecular Genetics*, **2013**, 22, 4914-28	5.6	51
96	Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency. *Molecular Therapy - Nucleic Acids*, **2013**, 2, e124	10.7	16
95	Therapeutic targeting of non-coding RNAs. *Essays in Biochemistry*, **2013**, 54, 127-45	7.6	44
94	RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis. *Frontiers in Molecular Neuroscience*, **2013**, 6, 40	6.1	51
93	Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective. *Journal of Nucleic Acids*, **2013**, 2013, 208245	2.3	4
92	Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy. *Current Pharmaceutical Design*, **2013**, 19, 2948-62	3.3	19
91	Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. *Journal of Controlled Release*, **2012**, 161, 635-44	11.7	290
90	Exosome-mediated delivery of siRNA in vitro and in vivo. *Nature Protocols*, **2012**, 7, 2112-26	18.8	366
89	The biogenesis and characterization of mammalian microRNAs of mirtron origin. *Nucleic Acids Research*, **2012**, 40, 438-48	20.1	73
88	Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. *Human Molecular Genetics*, **2012**, 21, R125-34	5.6	632
87	Optimizing tissue-specific antisense oligonucleotide-peptide conjugates. *Methods in Molecular Biology*, **2012**, 867, 415-35	1.4	6
86	Polyglutamine disease: from pathogenesis to therapy. *South African Medical Journal*, **2012**, 102, 481-4	1.5	5
85	Mirtrons, an emerging class of atypical miRNA. *Wiley Interdisciplinary Reviews RNA*, **2012**, 3, 617-32	9.3	56
84	RNA therapy for polyglutamine neurodegenerative diseases. *Expert Reviews in Molecular Medicine*, **2012**, 14, e3	6.7	9

83	Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. *Molecular Therapy - Nucleic Acids*, **2012**, 1, e39	10.7	105
82	Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. *Molecular Therapy - Nucleic Acids*, **2012**, 1, e38	10.7	137
81	Natural Antisense Makes Sense for Gene-specific Activation in Brain. *Molecular Therapy - Nucleic Acids*, **2012**, 1, e24	10.7	3
80	Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy. *Molecular Therapy - Nucleic Acids*, **2012**, 1, e62	10.7	34
79	Small RNA-Mediated Epigenetic Myostatin Silencing. *Molecular Therapy - Nucleic Acids*, **2012**, 1, e23	10.7	20
78	Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. *Molecular Therapy - Nucleic Acids*, **2012**, 1, e27	10.7	75
77	Artificial mirtron-mediated gene knockdown: functional DMPK silencing in mammalian cells. *Rna*, **2012**, 18, 1328-37	5.8	11
76	Exosomes and the emerging field of exosome-based gene therapy. *Current Gene Therapy*, **2012**, 12, 262-74	4.3	136
75	Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224. *Nucleic Acids Research*, **2012**, 40, 9863-75	20.1	34
74	Use of cell-penetrating-peptides in oligonucleotide splice switching therapy. *Current Gene Therapy*, **2012**, 12, 161-78	4.3	22
73	Targeting RNA to treat neuromuscular disease. *Nature Reviews Drug Discovery*, **2011**, 10, 621-37	64.1	120
72	DNA cage delivery to mammalian cells. *ACS Nano*, **2011**, 5, 5427-32	16.7	423
71	Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. *Neuroscience Research*, **2011**, 69, 337-42	2.9	136
70	D-amino acid oxidase knockdown in the mouse cerebellum reduces NR2A mRNA. *Molecular and Cellular Neurosciences*, **2011**, 46, 167-75	4.8	15
69	Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. *Lancet, The*, **2011**, 378, 595-605	40	682
68	Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease. *PLoS ONE*, **2011**, 6, e26194	3.7	12
67	Fitness effects of endemic malaria infections in a wild bird population: the importance of ecological structure. *Journal of Animal Ecology*, **2011**, 80, 1196-206	4.7	113
66	Infection dynamics of endemic malaria in a wild bird population: parasite species-dependent drivers of spatial and temporal variation in transmission rates. *Journal of Animal Ecology*, **2011**, 80, 1207-16	4.7	70

65	Molecular epidemiology of malaria prevalence and parasitaemia in a wild bird population. *Molecular Ecology*, **2011**, 20, 1062-76	5.7	103
64	Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nature Biotechnology*, **2011**, 29, 341-5	44.5	2697
63	Genetic therapies for RNA mis-splicing diseases. *Trends in Genetics*, **2011**, 27, 196-205	8.5	128
62	Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. *Neurobiology of Disease*, **2011**, 42, 360-7	7.5	492
61	Intranasal exosomes for treatment of neuroinflammation? Prospects and limitations. *Molecular Therapy*, **2011**, 19, 1754-6	11.7	12
60	RNA splicing: disease and therapy. *Briefings in Functional Genomics*, **2011**, 10, 151-64	4.9	62
59	The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy. *Journal of Molecular Medicine*, **2011**, 89, 1065-77	5.5	17
58	The acute inflammatory response to intranigral □synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. *Journal of Neuroinflammation*, **2011**, 8, 166	10.1	118
57	Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. *BioEssays*, **2011**, 33, 737-41	4.1	210
56	Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. *Molecular Therapy*, **2011**, 19, 1295-303	11.7	105
55	Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. *Human Molecular Genetics*, **2011**, 20, 413-21	5.6	63
54	PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. *Nucleic Acids Research*, **2011**, 39, 5284-98	20.1	164
53	Novel RNA-based strategies for therapeutic gene silencing. *Molecular Therapy*, **2010**, 18, 466-76	11.7	107
52	Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge. *Science Translational Medicine*, **2010**, 2, 25ps15	17.5	15
51	RNA-targeted splice-correction therapy for neuromuscular disease. *Brain*, **2010**, 133, 957-72	11.2	78
50	Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. *Molecular Therapy*, **2010**, 18, 1822-9	11.7	65
49	Identification of a novel muscle targeting peptide in mdx mice. *Peptides*, **2010**, 31, 1873-7	3.8	25
48	Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. *Molecular Therapy*, **2010**, 18, 819-27	11.7	71

47	Context-dependent effects of parental effort on malaria infection in a wild bird population, and their role in reproductive trade-offs. *Oecologia*, **2010**, 164, 87-97	2.9	28
46	Therapeutic gene silencing strategies for polyglutamine disorders. *Trends in Genetics*, **2010**, 26, 29-38	8.5	21
45	D-Serine metabolism in C6 glioma cells: Involvement of alanine-serine-cysteine transporter (ASCT2) and serine racemase (SRR) but not D-amino acid oxidase (DAO). *Journal of Neuroscience Research*, **2010**, 88, 1829-40	4.4	18
44	In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. *Journal of Gene Medicine*, **2010**, 12, 354-64	3.5	18
43	Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. *PLoS ONE*, **2009**, 4, e7232	3.7	44
42	Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2. *Molecular Biology of the Cell*, **2009**, 20, 521-9	3.5	64
41	A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. *Human Molecular Genetics*, **2009**, 18, 4405-14	5.6	119
40	Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. *Human Molecular Genetics*, **2009**, 18, R27-39	5.6	63
39	Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. *Lancet Neurology, The*, **2009**, 8, 918-28	24.1	557
38	Phenotypic correlates of Clock gene variation in a wild blue tit population: evidence for a role in seasonal timing of reproduction. *Molecular Ecology*, **2009**, 18, 2444-56	5.7	80
37	Biological gene delivery vehicles: beyond viral vectors. *Molecular Therapy*, **2009**, 17, 767-77	11.7	249
36	Seasonal variation in Plasmodium prevalence in a population of blue tits Cyanistes caeruleus. *Journal of Animal Ecology*, **2008**, 77, 540-8	4.7	126
35	Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. *Nucleic Acids Research*, **2008**, 36, 6418-28	20.1	146
34	Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. *Human Molecular Genetics*, **2008**, 17, 3909-18	5.6	169
33	Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. *Molecular Therapy*, **2008**, 16, 38-45	11.7	117
32	Th1 cytokines are upregulated by adenoviral vectors in the brains of primed mice. *NeuroReport*, **2008**, 19, 1187-92	1.7	4
31	Hairpin DNAzymes: a new tool for efficient cellular gene silencing. *Journal of Gene Medicine*, **2007**, 9, 727-38	3.5	27
30	Genome-wide atlas of gene expression in the adult mouse brain. *Nature*, **2007**, 445, 168-76	50.4	3675

29	Within-population variation in prevalence and lineage distribution of avian malaria in blue tits, Cyanistes caeruleus. *Molecular Ecology*, **2007**, 16, 3263-73	5.7	161
28	Knockdown of SMN by RNA interference induces apoptosis in differentiated P19 neural stem cells. *Brain Research*, **2007**, 1183, 1-9	3.7	14
27	Parasites entangled in food webs. *Trends in Parasitology*, **2007**, 23, 8-10	6.4	13
26	Modulating the expression of disease genes with RNA-based therapy. *PLoS Genetics*, **2007**, 3, e109	6	73
25	RNA interference based gene therapy for neurological disease. *Briefings in Functional Genomics & Proteomics*, **2007**, 6, 40-9		13
24	Readministration of adenoviral gene delivery to dopamine neurons. *NeuroReport*, **2007**, 18, 1609-14	1.7	5
23	The hitchhiker's guide to avian malaria. *Trends in Ecology and Evolution*, **2006**, 21, 5-7	10.9	2
22	Learned kin recognition cues in a social bird. *Nature*, **2005**, 434, 1127-30	50.4	194
21	Delivering RNA interference to the mammalian brain. *Current Gene Therapy*, **2005**, 5, 399-410	4.3	48
20	Olfactory cues and Vespula wasp recognition by honey bee guards. *Apidologie*, **2004**, 35, 461-468	2.3	11
19	RNA interference: from model organisms towards therapy for neural and neuromuscular disorders. *Human Molecular Genetics*, **2004**, 13 Spec No 2, R275-88	5.6	50
18	Neuropathological consequences of delivering an adenoviral vector in the rat brain. *Journal of Gene Medicine*, **2004**, 6, 740-50	3.5	5
17	Survival of motor neuron gene downregulation by RNAi: towards a cell culture model of spinal muscular atrophy. *Molecular Brain Research*, **2004**, 120, 145-50		15
16	Characterisation of catalytic nucleic acids targeting the survival of motor neuron messenger RNA. *Neuroscience Research Communications*, **2003**, 32, 95-106		1
15	Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. *Human Molecular Genetics*, **2003**, 12, 2637-44	5.6	55
14	Therapeutic gene silencing in the nervous system. *Human Molecular Genetics*, **2003**, 12 Spec No 2, R279-84	5.6	34
13	Ribozymes and siRNA for the treatment of diseases of the nervous system. *Current Opinion in Molecular Therapeutics*, **2003**, 5, 383-8		4
12	Humoral immune responses to adenovirus vectors in the brain. *Journal of Neuroimmunology*, **2000**, 103, 8-15	3.5	36

11	Cytokine gene expression following neural grafts. *Experimental Brain Research*, **1999**, 126, 281-8	2.3	9
10	Ribozyme-mediated trans-splicing of a trinucleotide repeat. *Nature Genetics*, **1998**, 18, 378-81	36.3	125
9	Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. *European Journal of Immunology*, **1998**, 28, 3904-16	6.1	45
8	Ribozymes as therapeutic tools for genetic disease. *Human Molecular Genetics*, **1998**, 7, 1649-53	5.6	32
7	Immune responses to adenoviral vectors during gene transfer in the brain. *Human Gene Therapy*, **1997**, 8, 253-65	4.8	89
6	Immune responses to adenovirus vectors in the nervous system. *Trends in Neurosciences*, **1996**, 19, 497-501	13.3	144
5	Morphological assessment of grafted rat and mouse cortical neurons: a light and electron microscopic study. *Journal of Comparative Neurology*, **1994**, 341, 78-94	3.4	7
4	Specific patterns of defective HSV-1 gene transfer in the adult central nervous system: implications for gene targeting. *Experimental Neurology*, **1994**, 130, 127-40	5.7	36
3	Cytokines and peripheral tolerance to alloantigen. *Immunological Reviews*, **1993**, 133, 5-18	11.3	67
2	GAPDH controls extracellular vesicle biogenesis and enhances therapeutic potential of EVs in silencing the Huntingtin gene in mice via siRNA delivery		2
1	Engineering of extracellular vesicles for display of protein biotherapeutics		3